Antibiotics Deals are Blossoming
Biotech has joined the new war on infectious diseases-for sound business reasons.
You may also be interested in...
It's a gloomy time for antibiotic R&D: higher regulatory hurdles and commercial challenges have forced many companies to leave the market. But a few major players and boutique firms remain committed to the field. What do they see that the rest of the industry is overlooking?
Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.
The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Eli Lilly to develop kidney disease and diabetes assets.